Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (821-830 of 962) with videos related to

Pageof 97
Sort By:
Journal of the American College of Cardiology|February 7, 2018
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary DiseaseSameer Bansilal, Marc P Bonaca, Jan H Cornel, et al.
Lancet (London, England)|September 1, 2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trialPascal Vranckx, Marco Valgimigli, Peter Jüni, et al.
Journal of the American Heart Association|March 1, 2022
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS TrialFelice Gragnano, Marcel Zwahlen, Pascal Vranckx, et al.
The New England Journal of Medicine|November 16, 2006
Coronary intervention for persistent occlusion after myocardial infarctionJudith S Hochman, Gervasio A Lamas, Christopher E Buller, et al.
Circulation. Cardiovascular Interventions|August 26, 2020
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary InterventionHironori Hara, Kuniaki Takahashi, Norihiro Kogame, et al.
European Heart Journal|March 28, 2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics studyDeepak L Bhatt, Guillaume Paré, John W Eikelboom, et al.
The New England Journal of Medicine|November 1, 2013
Bivalirudin started during emergency transport for primary PCIPhilippe Gabriel Steg, Arnoud van 't Hof, Christian W Hamm, et al.
Circulation. Genomic and Precision Medicine|January 12, 2021
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic DiseaseNicholas A Marston, Giorgio E M Melloni, Yared Gurmu, et al.
Journal of the American College of Cardiology|August 31, 2019
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass SurgeryShaun G Goodman, Philip E Aylward, Michael Szarek, et al.
European Heart Journal|August 10, 2019
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trialPatrick W Serruys, Kuniaki Takahashi, Ply Chichareon, et al.
Pageof 97

Showing results (821-830 of 962) with videos related to

Sort By:
Pageof 97
Journal of the American College of Cardiology|February 7, 2018
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary DiseaseSameer Bansilal, Marc P Bonaca, Jan H Cornel, et al.
Lancet (London, England)|September 1, 2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trialPascal Vranckx, Marco Valgimigli, Peter Jüni, et al.
Journal of the American Heart Association|March 1, 2022
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS TrialFelice Gragnano, Marcel Zwahlen, Pascal Vranckx, et al.
The New England Journal of Medicine|November 16, 2006
Coronary intervention for persistent occlusion after myocardial infarctionJudith S Hochman, Gervasio A Lamas, Christopher E Buller, et al.
Circulation. Cardiovascular Interventions|August 26, 2020
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary InterventionHironori Hara, Kuniaki Takahashi, Norihiro Kogame, et al.
European Heart Journal|March 28, 2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics studyDeepak L Bhatt, Guillaume Paré, John W Eikelboom, et al.
The New England Journal of Medicine|November 1, 2013
Bivalirudin started during emergency transport for primary PCIPhilippe Gabriel Steg, Arnoud van 't Hof, Christian W Hamm, et al.
Circulation. Genomic and Precision Medicine|January 12, 2021
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic DiseaseNicholas A Marston, Giorgio E M Melloni, Yared Gurmu, et al.
Journal of the American College of Cardiology|August 31, 2019
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass SurgeryShaun G Goodman, Philip E Aylward, Michael Szarek, et al.
European Heart Journal|August 10, 2019
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trialPatrick W Serruys, Kuniaki Takahashi, Ply Chichareon, et al.
Pageof 97